JPMorgan Chase & Co. Raises Biogen (NASDAQ:BIIB) Price Target to $185.00

Biogen (NASDAQ:BIIB) had its price objective hoisted by investment analysts at JPMorgan Chase & Co. from $175.00 to $185.00 in a report issued on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 0.34% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Royal Bank Of Canada reduced their target price on Biogen from $233.00 to $213.00 and set an “outperform” rating for the company in a report on Tuesday, April 7th. HSBC lifted their target price on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a report on Tuesday, March 17th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Biogen in a report on Monday, February 9th. Guggenheim lifted their target price on Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Argus raised Biogen to a “hold” rating in a report on Thursday, April 9th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $211.31.

Biogen Trading Down 1.9%

Shares of BIIB opened at $184.38 on Thursday. The business has a 50-day moving average of $185.13 and a 200 day moving average of $175.03. Biogen has a fifty-two week low of $115.25 and a fifty-two week high of $202.41. The firm has a market cap of $27.06 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the firm posted $3.44 EPS. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts forecast that Biogen will post 15.77 EPS for the current year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Reflection Asset Management purchased a new position in Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC increased its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the last quarter. Accredited Wealth Management LLC increased its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the last quarter. First Horizon Corp bought a new position in shares of Biogen in the 4th quarter worth $30,000. Finally, WFA of San Diego LLC bought a new position in shares of Biogen in the 2nd quarter worth $32,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.